Digital Currency X Technology Announces Pricing of $5.0 Million Registered Direct Offering

DCX is raising approximately $5 million via a registered direct offering to fund working capital, crypto treasury operations and D&O insurance.

Rhea-AI Summary

Digital Currency X Technology (DCX) priced a registered direct offering of 23,809,530 Ordinary Shares (or pre-funded warrants) and accompanying warrants to raise about $5.0 million.

Investors will pay a combined purchase price of $0.21 per Ordinary Share (or pre-funded warrant) plus one Series A and one Series B warrant. Series A warrants have a $0.44 exercise price, are immediately exercisable, and expire 5 years from issuance. Series B warrants have a $0.21 exercise price per unit, are immediately exercisable, and expire 30 days after issuance. Closing is expected on or about September 21, 2026, and the company plans to use net proceeds for working capital, digital asset treasury activities, and director and officer insurance.

Positive

• Registered direct offering expected to provide gross proceeds of approximately $5.0 million
• Warrants are immediately exercisable, potentially enabling faster additional capital inflows if exercised

Negative

• Issuance of 23,809,530 new Ordinary Shares (or pre-funded warrants) at $0.21 increases outstanding equity
• Deal structure includes Series A and Series B warrants exercisable for additional Ordinary Shares, expanding potential future share count

News Explained

The agreement is signed but not closed; completing it would add shares and potentially more through warrants, reducing existing holders’ percentage ownership.

DCX has entered a definitive agreement, but the offering is not yet closed; if completed, the sale of 23,809,530 shares or pre-funded warrants, plus warrant exercise rights, would create additional shares and reduce existing holders’ percentage ownership.

Each Series B warrant can be exercised for one share and a new Series A warrant, so the disclosed structure provides more than one potential route to additional shares; the Series B warrants expire 30 days after issuance, while the Series A warrants expire five years after issuance.

The expected September 21, 2026 closing and the related prospectus supplement are the next milestones: the effective Form F-3 provides selling capacity, while the supplement sets the final terms of this specific sale.

Argus 15 min delay

-67.53% vs previous close $0.14 last price 1282.5x rel. volume Open Argus

Details

Market reaction after registered direct offering: DCX -67.53%

-64.1% Trough in 13 min

$0.13 $0.43 Day Range

$50.24M Market Cap

Following this news, DCX has declined 67.53%, reflecting a significant negative market reaction. Argus tracked a trough of -64.1% from its starting point during tracking. Our momentum scanner has triggered 128 alerts so far, indicating very high trading interest and price volatility. The stock is currently trading at $0.14. Trading volume is exceptionally heavy at 1282.5x the average, suggesting significant selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The stock is dropping -67.5% following this news. On Jun 25, the prior US$700 million private placem...

Analysis

The stock is dropping -67.5% following this news. On Jun 25, the prior US$700 million private placement had a recorded 36.65% decline in its 24-hour price reaction; that financing record provided relevant context for this new offering with accompanying warrants.

Key Figures

Gross Proceeds: approximately $5.0 million Shares Offered: 23,809,530 Ordinary Shares Purchase Price: $0.21 per Ordinary Share +5 more

Gross Proceeds

approximately $5.0 million

Registered direct offering before fees and expenses

Shares Offered

23,809,530 Ordinary Shares

Ordinary Shares or pre-funded warrants

Purchase Price

$0.21 per Ordinary Share

Includes accompanying Series A and Series B warrants

Series A Exercise Price

$0.44 per Ordinary Share

Immediately exercisable; expires 5 years after issuance

Series A Warrant Term

5 years

From the date of issuance

Series B Exercise Price

$0.21 per unit

Immediately exercisable; each unit includes one share and one Series A warrant

Series B Warrant Term

30 days

From the date of issuance

Expected Closing

September 21, 2026

Subject to customary closing conditions

Historical Context

1 past event · Latest: Jun 25

1 event

1. Jun 25

   Private placement

   24h Move

   -36.6%

   Prior US$700 million private placement recorded a negative 24-hour price reaction

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, pre-funded warrants, anti-dilution, shelf registration statement, +1 more

5 terms

registered direct offering financial

"in a registered direct offering, together with accompanying Series A warrants"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

pre-funded warrants financial

"or pre-funded warrants in lieu thereof"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

anti-dilution financial

"subject to customary anti-dilution adjustments"

A provision that protects an investor’s ownership stake or the value of convertible securities when a company issues new shares at a lower price. It adjusts the investor’s number of shares or the conversion price so their percentage of ownership or economic interest isn’t unfairly reduced — like getting a bigger slice of cake if the baker cuts more pieces, preserving your share of the whole.

shelf registration statement regulatory

"offered pursuant to a shelf registration statement on Form F-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form f-3 regulatory

"a shelf registration statement on Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Digital Currency X Technology Inc. (Nasdaq: DCX) (“DCX” or the “Company”), a digital asset treasury management company, today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of 23,809,530 Ordinary Shares (or pre-funded warrants in lieu thereof) in a registered direct offering, together with accompanying Series A warrants and Series B warrants, at a combined purchase price of $0.21 per Ordinary Share (or pre-funded warrant) and accompanying warrants, for gross proceeds to the Company of approximately $5.0 million, before deducting placement agent fees and other estimated offering expenses.

Each Ordinary Share is being sold together with one Series A warrant and one Series B warrant. The Series A warrants are exercisable for Ordinary Shares, have an initial exercise price of $0.44 per Ordinary Share, are exercisable immediately upon issuance and will expire 5 years from the date of issuance. Each Series B warrant is exercisable for one unit consisting of (i) one Ordinary Share and (ii) one new Series A warrant to purchase one Ordinary Share on the same terms as the original Series A warrants. The Series B warrants have an initial exercise price of $0.21 per unit, are exercisable immediately upon issuance and will expire 30 days from the date of issuance. The exercise prices of the Series A and Series B Warrants are subject to customary anti-dilution adjustments in connection with share splits, share combinations, dividend distributions, subsequent equity sales and other corporate restructurings.

The offering is expected to close on or about September 21, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds of this offering for working capital and general corporate purposes, which may include the acquisition, custody, holding, staking, management and disposition of digital assets and cryptocurrencies and related treasury and business operations, and the purchase of insurance coverage for the Company’s directors and officers.

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

The securities sold in the offering are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-281314), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 16, 2024. The offering of the securities will be made only by means of a prospectus supplement that forms a part of such registration statement. A prospectus supplement relating to the securities offered in the offering will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the offering, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3500.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Digital Currency X Technology

Digital Currency X Technology Inc. (Nasdaq: DCX) is a Cayman Islands exempted company headquartered in Hong Kong. Following the divestiture of its former China-based automotive business, the Company focuses on the digital asset sector, including on-chain data and information services provided through its DexTrader platform and digital asset treasury and ecosystem initiatives.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the completion, timing and size of the offering and the anticipated use of proceeds. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict, including whether the Company will consummate the offering on the anticipated terms or at all, the satisfaction of customary closing conditions, prevailing market and other conditions, and the risks and uncertainties described under "Item 3.D. Risk Factors" in the Company’s most recent Annual Report on Form 20-F and in the Company’s other reports filed with or furnished to the U.S. Securities and Exchange Commission, copies of which are available at www.sec.gov. The Company’s actual results could differ materially from those expressed or implied by the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key terms of the Series A warrants in the DCX offering?

Each Ordinary Share is sold with one Series A warrant. Each Series A warrant is exercisable for Ordinary Shares at an initial exercise price of $0.44 per share, is exercisable immediately upon issuance, and will expire 5 years from the date of issuance. The exercise price is subject to customary anti-dilution adjustments related to share splits, combinations, dividends, subsequent equity sales and other corporate restructurings.

How are the Series B warrants structured in the DCX financing?

Each Series B warrant is exercisable for one unit consisting of (i) one Ordinary Share and (ii) one new Series A warrant with the same terms as the original Series A warrants. Series B warrants have an initial exercise price of $0.21 per unit, are exercisable immediately upon issuance, and will expire 30 days from the date of issuance. Their exercise prices are also subject to customary anti-dilution adjustments.

When is the DCX registered direct offering expected to close?

The offering is expected to close on or about September 21, 2026, subject to the satisfaction of customary closing conditions.

How does DCX plan to use the net proceeds from this offering?

DCX intends to use the net proceeds for working capital and general corporate purposes. This may include the acquisition, custody, holding, staking, management and disposition of digital assets and cryptocurrencies and related treasury and business operations, as well as the purchase of insurance coverage for the company’s directors and officers.

Under which registration statement is this offering being made?

The securities are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-281314), which was declared effective by the U.S. Securities and Exchange Commission on August 16, 2024. The offering will be made only by means of a prospectus supplement that forms part of this registration statement.

Where can investors obtain the prospectus supplement for the DCX offering?

When available, the prospectus supplement and accompanying prospectus can be obtained from the SEC’s website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3500.

Who is acting as placement agent for the DCX registered direct offering?

Maxim Group LLC is acting as the sole placement agent in connection with the offering.